Roche (RHHBY) announced that it has expanded its collaboration with Janssen (JNJ) to create companion diagnostics for targeted therapies, further strengthening research and innovation activities. The new, expanded agreement broadens opportunities for Roche and Janssen to collaborate in the precision medicine field with multiple companion diagnostics technologies, including immunohistochemistry, or IHC, digital pathology, next generation sequencing, polymerase chain reaction and immunoassays. Examples of projects that may develop as a result of this collaboration include exploring data and tissue image analysis and the development of a new IHC assay to support patient identification and enrollment for personalized treatment.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RHHBY:
- New phase III data show Roche’s Vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO)
- [Ad hoc announcement pursuant to Art. 53 LR] Transaction in Roche bearer shares
- Bill Anderson to become CEO of Bayer AG
- Roche reports COMMODORE 2 study met co-primary efficacy endpoints
- Roche announces positive data from global phase III programme for crovalimab in PNH, a rare life-threatening blood condition
